Results 221 to 230 of about 7,376 (242)
Some of the next articles are maybe not open access.
American journal of dermatopathology, 2023
: Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a cutaneous drug eruption with a characteristic distribution of erythema on the gluteal/inguinal region and intertriginous areas with unclear pathogenesis.
K. Chaudet +5 more
semanticscholar +1 more source
: Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a cutaneous drug eruption with a characteristic distribution of erythema on the gluteal/inguinal region and intertriginous areas with unclear pathogenesis.
K. Chaudet +5 more
semanticscholar +1 more source
Australasian Journal of Dermatology, 2022
Symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE), previously termed drug‐related baboon syndrome, is an uncommon drug eruption. It is characterized by symmetrical erythema involving the gluteal and/or inguinal area in association ...
C. Spigariolo +5 more
semanticscholar +1 more source
Symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE), previously termed drug‐related baboon syndrome, is an uncommon drug eruption. It is characterized by symmetrical erythema involving the gluteal and/or inguinal area in association ...
C. Spigariolo +5 more
semanticscholar +1 more source
An intertriginous eruption in an infant
Pediatric dermatology, 2022, topical preparations, excessive sweating, and occlusion have all been purported triggers. 3 Many of the rare reports of pediatric GP have been linked to the over-treatment of diaper dermatitis with topical products containing zinc oxide.
Adaora Ewulu +2 more
semanticscholar +1 more source
Contact Dermatitis, 2021
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) refers to a symmetrically distributed cutaneous rash involving the perineum and folds following exposure to a systemic drug, in the absence of systemic signs and symptoms, and ...
M. Megna +7 more
semanticscholar +1 more source
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) refers to a symmetrically distributed cutaneous rash involving the perineum and folds following exposure to a systemic drug, in the absence of systemic signs and symptoms, and ...
M. Megna +7 more
semanticscholar +1 more source
Journal of Cosmetic Dermatology, 2021
Symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) refers to an uncommon cutaneous adverse reaction that symmetrically involves the buttock and intertriginous areas after systemic exposure to the offending drug and is previously ...
Jing Liu, Lin‐Feng Li
semanticscholar +1 more source
Symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) refers to an uncommon cutaneous adverse reaction that symmetrically involves the buttock and intertriginous areas after systemic exposure to the offending drug and is previously ...
Jing Liu, Lin‐Feng Li
semanticscholar +1 more source
Clincal and Experimental Dermatology, 2021
The diagnosis of the most common cutaneous T-cell lymphomas (CTCLs), mycosis fungoides (MF) and Sézary syndrome (SS) are often delayed because of unspecific clinical and histopathological findings in the early stages of the disease.1 In SS, erythroderma ...
A. Amir Ali +5 more
semanticscholar +1 more source
The diagnosis of the most common cutaneous T-cell lymphomas (CTCLs), mycosis fungoides (MF) and Sézary syndrome (SS) are often delayed because of unspecific clinical and histopathological findings in the early stages of the disease.1 In SS, erythroderma ...
A. Amir Ali +5 more
semanticscholar +1 more source
Clinical Cancer Investigation Journal, 2021
Over recent years, targeted therapy has become one of the most important innovations in cancer treatment. Agents targeting the epidermal growth factor receptor (EGFR) are administered in patients with advanced, recurrent or metastatic malignancy.
R. Coppola +3 more
semanticscholar +1 more source
Over recent years, targeted therapy has become one of the most important innovations in cancer treatment. Agents targeting the epidermal growth factor receptor (EGFR) are administered in patients with advanced, recurrent or metastatic malignancy.
R. Coppola +3 more
semanticscholar +1 more source